A preclinical study tested a hyalurosomal hydrogel designed to co-deliver nifedipine and citicoline sodium, using a nanovesicle gel formulation intended to improve ocular penetration. In rabbits, the therapy produced a 51.85% maximum reduction in intraocular pressure compared with a control solution and showed 2.2-fold deeper corneal penetration. The authors reported the formulation also outperformed a marketed glaucoma drop in the same experimental framework, pointing to potential advantages in sustained delivery and tissue uptake. While the work remains preclinical, it targets a key challenge in glaucoma—achieving effective drug exposure in ocular tissues. For translational planning, the next steps would typically include formulation stability, repeat-dose tolerability, and exploration in additional models that better recapitulate optic nerve and retinal outcomes. The dual-drug approach also suggests a strategy of combining complementary mechanisms rather than relying on a single active to manage eye pressure.